FINWIRES · TerminalLIVE
FINWIRES

Bellevue Gold Logs Earnings in Fiscal 2026, Revenue Up; Shares Up 4%

By

Bellevue Gold (ASX:BGL) logged AU$0.0047 in earnings per share for the fiscal 2026, compared with a loss of AU$0.035 a year ago, a Tuesday filing showed.

For the 12 months ended June 30, revenue was AU$576.3 million versus AU$505.8 million previously, the Australia-listed gold miner added.

The company expects fiscal 2027 gold production of 150,000 to 170,000 ounces at a project all-in sustaining cost of AU$2,800 to AU$3,100 per ounce. Non-sustaining capital expenditure is expected at AU$90 million to AU$100 million, while exploration expenditure is forecast at AU$25 million to AU$30 million.

The company's shares rose past 4% in recent Tuesday trade.

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA